Zhitong Finance App News, Luxin Biotechnology (01084) issued an announcement. After preliminary review of the available information (including but not limited to the Group's unaudited comprehensive management accounts for the six months ended June 30, 2026 (reporting period)), the board of directors hereby informs the Company's shareholders (shareholders) and interested investors that during the reporting period, the Company expects to obtain a net loss attributable to the owners of the Company ranged from approximately RMB 1 million to RMB 4 million, while the net loss due to the Company's owners for the six months ended June 30, 2025 was RMB 1.07 million yuan.

The Group's improved performance was mainly due to increased sales of carrageenan products due to the Group's competitive pricing strategy, which contributed to revenue and gross profit growth during the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.